VERSEAU THERAPEUTICS

Verseau Therapeutics was founded in 2017 by Bob Langer, Dan Anderson, Tatiana Novobrantseva and Igor Feldman to discover and develop a broad pipeline of novel macrophage targets that stimulate their repolarization... At Verseau, we are advancing a new class of cancer immunotherapies to stimulate the conversion of immuno-suppressive and pro-tumorigenic M2 macrophages into pro-inflammatory M1 macrophages. This transformation, called macrophage repolarization, induces a coordinated immune response to fight cancer... Verseau's macrophage repolarization target discovery engine leverages human and disease biology, as well as computational approaches in a patient-focused discovery process. We are developing a robust pipeline of first-in-class monoclonal antibodies that bind to novel macrophage repolarization targets. Our lead candidates, VTX-0811 targeting PSGL-1 and VTX-1218 targeting VSIG4, are rapidly progressing toward clinical trials informed by state-of-the-art analytics and..

Also known as: Verseau, Verseau Therapeutics, Inc.

Primary location: Auburndale United States